The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Basit Öğe Kaydı
dc.authoridgülmez, ahmet/0000-0002-3353-344X
dc.authoridKESKİNKILIÇ, MERVE/0000-0002-3342-3144
dc.authoridErgun, Yakup/0000-0003-4784-6743
dc.authoridbilgin, burak/0000-0003-1717-8246
dc.authoridAk, Naziye/0000-0001-5790-7066
dc.authoridÜnal, Çağlar/0000-0003-3245-1570
dc.authoridAkkoc Mustafayev, Fatma Nihan/0000-0001-7024-4156
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidgülmez, ahmet/ABI-8218-2020
dc.authorwosidKESKİNKILIÇ, MERVE/HNR-2564-2023
dc.authorwosidErgun, Yakup/N-3273-2018
dc.authorwosidYumuk, Perran Fulden/A-6189-2018
dc.authorwosidbilgin, burak/A-9416-2018
dc.authorwosidAy, Murat/GSI-4353-2022
dc.contributor.authorHizal, Mutlu
dc.contributor.authorBilgin, Burak
dc.contributor.authorPaksoy, Nail
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorKahraman, Seda
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorGuven, Deniz Can
dc.date.accessioned2024-08-04T20:52:16Z
dc.date.available2024-08-04T20:52:16Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive effect in patients with advanced NSCLC who received first-line Alectinib as ALK-TKI. Materials and methods This retrospective study included patients with advanced-stage NSCLC who received alectinib as a first-line ALK-TKI and whose percentage of ALK-positive cells was determined by FISH at 27 different centers. Patients who received any ALK-TKI before alectinib were not included in the study. Patients were separated into two groups according to the median (40%) value of the percentage of ALK-positive cells (high-positive group >= 40% and low-positive group < 40%). The primary endpoint was PFS, and the secondary endpoints were OS, ORR, and PFS of the subgroups based on different threshold values for the percentage of ALK-positive cells. Results 211 patients were enrolled (48.3% female, 51.7% male) to study. 37% (n = 78) of the patients had received chemotherapy previously. After a median of 19.4 months of follow-up, the median PFS was not reached in the high-positive group (n = 113), but it was 10.8 months in the low-positive group (n = 98) (HR 0.39; 95% CI 0.25-0.60, p < 0.001). The median OS in the high-positive group was not reached, whereas it was 22.8 months in the low-positive group (HR 0.37; 95% CI 0.22-0.63, p < 0.001). ORR was significantly higher in the high-positive group (87.2 vs. 68.5%; p = 0.002). According to the cut-off values of < 20%, 20-39%, 40-59%, and >= 60%, the median PFS was 4.5, 17.1, and 26 months, respectively, and could not be reached in the >= 60% group. Conclusion Our study demonstrated that the efficacy of alectinib varies significantly across patient subgroups with different percentages of ALK-positive cells. If these findings are prospectively validated, the percentage of ALK-positive cells may be used as a stratification factor in randomized trials comparing different ALK-TKIs.en_US
dc.identifier.doi10.1007/s00432-022-04252-2
dc.identifier.endpage4148en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue8en_US
dc.identifier.pmid36048274en_US
dc.identifier.scopus2-s2.0-85137039744en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage4141en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04252-2
dc.identifier.urihttps://hdl.handle.net/11616/100863
dc.identifier.volume149en_US
dc.identifier.wosWOS:000849293900006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlectiniben_US
dc.subjectPercentage of ALK-positive cellsen_US
dc.subjectBreak-aparten_US
dc.subjectPredictiveen_US
dc.subjectResponseen_US
dc.titleThe percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu